-transparent.png){kind=logo}
Twenty-six of 300 patients (9%) with rheumatoid arthritis (RA) developed penicillamine-induced proteinuria. The mean daily dose and duration of therapy at onset of proteinuria were 591 mg and 9 months, respectively, while the mean duration of proteinuria was 5.5 months. However, six patients developed proteinuria at 250 mg/d and six after 9 months of therapy. Twelve patients were successfully either restarted (five) or maintained (seven) on penicillamine with resolution of proteinuria. No permanent renal impairment occurred. Positive risk factors included the presence of HLA-B8 and DR3 and prior gold-induced proteinuria. Patients with prior gold-induced proteinuria should be observed more carefully, but tissue typing is not recommended as proteinuria is reversible. Furthermore, penicillamine can be restarted or maintained in these patients if the RA has responded favorably to the drug.
H B Stein, and
M L Schroeder, and
A M Dillon
January 1984,
Scandinavian journal of rheumatology,
H B Stein, and
M L Schroeder, and
A M Dillon
February 1981,
The Johns Hopkins medical journal,
H B Stein, and
M L Schroeder, and
A M Dillon
October 1968,
Postgraduate medical journal,
H B Stein, and
M L Schroeder, and
A M Dillon
January 1981,
The Journal of rheumatology. Supplement,
H B Stein, and
M L Schroeder, and
A M Dillon
June 1979,
Annals of the rheumatic diseases,
H B Stein, and
M L Schroeder, and
A M Dillon
February 1968,
The Journal of urology,
H B Stein, and
M L Schroeder, and
A M Dillon
October 2018,
Transplantation proceedings,
H B Stein, and
M L Schroeder, and
A M Dillon
December 1983,
The Journal of rheumatology,
H B Stein, and
M L Schroeder, and
A M Dillon
June 1992,
Clinical rheumatology,
H B Stein, and
M L Schroeder, and
A M Dillon
February 2022,
Oncology letters,
